Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. November 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Registration Is Now Open For The Tribe Public Webinar Event On November 30, 2021 “A Town Hall Q&A Event With Atossa Therapeutics Management Team”

SEATTLE, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
15. November 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

SEATTLE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...
21. Oktober 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics CEO Dr. Steven Quay Emphasizes Importance of Breast Cancer Screening During Breast Cancer Awareness Month

SEATTLE, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Dr. Steven Quay, CEO of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative...
30. September 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

SEATTLE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
07. September 2021 17:20 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

Leading proxy advisory firms ISS and Glass Lewis recommend voting in favor Atossa establishes intended criteria for non-use of additional shares for financing transactions SEATTLE, Sept. 07, 2021 ...
02. September 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden

SEATTLE, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
13. August 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting

SEATTLE, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and...
05. August 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021

SEATTLE, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
07. Juli 2021 09:30 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia

Nebulized formulation being developed to improve lung function in both active-disease COVID-19 patients and “Long Haul” patients with post-infection pulmonary disease SEATTLE, July 07, 2021 (GLOBE...
16. Juni 2021 09:00 ET | Quelle: Atossa Therapeutics, Inc.

Atossa Therapeutics Set to Be Included in the Russell 2000 and Russell 3000 Indexes

SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...

Vorherige Seite

Nächste Seite